202 related articles for article (PubMed ID: 27824043)
1. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
Sanford NN; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):79-84. PubMed ID: 27824043
[TBL] [Abstract][Full Text] [Related]
2. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
[TBL] [Abstract][Full Text] [Related]
3. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
[TBL] [Abstract][Full Text] [Related]
4. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.
Patel SA; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):234-240. PubMed ID: 28117382
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.
Giacalone NJ; Wu J; Chen MH; Renshaw A; Loffredo M; Kantoff PW; D'Amico AV
J Clin Oncol; 2016 Nov; 34(31):3781-3786. PubMed ID: 27601545
[TBL] [Abstract][Full Text] [Related]
8. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
McDuff SGR; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
Cancer; 2018 Apr; 124(7):1391-1399. PubMed ID: 29338073
[TBL] [Abstract][Full Text] [Related]
9. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.
Huynh MA; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1158-67. PubMed ID: 27209511
[TBL] [Abstract][Full Text] [Related]
10. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
11. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
[TBL] [Abstract][Full Text] [Related]
12. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
Nanda A; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA; 2009 Aug; 302(8):866-73. PubMed ID: 19706860
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
[TBL] [Abstract][Full Text] [Related]
14. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
Mahal BA; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Natl Compr Canc Netw; 2018 Jun; 16(6):727-734. PubMed ID: 29891524
[No Abstract] [Full Text] [Related]
15. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
16. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
19. Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk.
Braunstein LZ; Chen MH; Dosoretz DE; Salenius SA; Katin MJ; Nanda A; D'Amico AV
Clin Genitourin Cancer; 2015 Dec; 13(6):555-61. PubMed ID: 26003267
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
